A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

NCT00486811 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

990

Enrollment

INDUSTRY

Sponsor class

Conditions

Pain
Knee Osteoarthritis

Interventions

DRUG: Tapentadol ER (100 to 250 mg twice daily)
DRUG: Matching Placebo (twice daily)
DRUG: Oxycodone CR (20 to 50 mg twice daily)

Sponsor

Grünenthal GmbH

Collaborators

[object Object]